Street View: Korro Bio plummets after disappointing drug trial

Korro Bio

13/11/2025 13:42

** Shares of drug developer Korro Bio  plunge 76.8% to $7.27 premarket

** KRRO on Wednesday said its experimental drug, KRRO-110, for a rare lung and liver disease failed to reach expected levels, and also paused its licensing deal with Novo Nordisk 

A SIGNIFICANT SETBACK

** RBC ("sector perform," PT: cut to $8 from $85) says it is disappointed by the data, company going into cash preservation mode by reducing the workforce by 34%

** Chardan Capital ("neutral," PT: $7): believes KRRO will require new human clinical data, expected in 2027, to rebuild investor confidence in its OPERA design platform

** B. Riley Securities ("buy," PT: $19) says the drug failed mainly because its delivery method, LNP (lipid nanoparticles), which didn’t work well in diseased livers and the drug wasn’t strong enough

** H.C.Waineright & Co ("neutral") says Korro is dropping KRRO-110 and shifting to a GalNAc-based AATD drug, but the new candidate won’t arrive until 1H26, leaving it behind rivals and raising doubts about its ability to turn lab success into real-world results

** William Blair ("market perform") says KRRO-110 clinical profile looks non-competitive at the moment

 (Reporting by Sanskriti Shekhar in Bengaluru)

 ((Sanskriti.Shekhar@thomsonreuters.com))